The Medical Advisor

Abstract Berberine has demonstrated glucose-lowering efficacy comparable to metformin through activation of AMP-activated protein kinase (AMPK). Beyond glycemic control, it modulates lipid metabolism, gut microbiota, inflammation, and oncogenic pathways including PI3K/Akt/mTOR and STAT3. This review examines clinical and preclinical evidence, advanced protocols, and future directions for diabetes and cancer applications. Keywords: Berberine, Type 2 Diabetes Mellitus, Metformin, AMP-activated Protein Kinase (AMPK), Nutraceuticals, Cancer Metabolism, Glycemic Control, mTOR Signaling Introduction Type 2 diabetes mellitus (T2DM) is a global health challenge, affecting over 500 million adults worldwide, with prevalence projected to increase due to aging populations, obesity, and sedentary lifestyles. Chronic hyperglycemia, insulin resistance, and low-grade systemic inflammation characterize T2DM, leading to microvascular complications such as nephropathy, retinopathy, and neuropathy, as w...

In the realm of integrative oncology, few natural compounds hold as much promise for amplifying repurposed therapies like fenbendazole as curcumin , berberine , and quercetin . These plant-derived powerhouses—staples in the updated Joe Tippens Protocol—aren't just buzzwords; they're backed by a surge of 2023-2025 research showing synergistic effects that could enhance fenbendazole's microtubule disruption and metabolic targeting in cancers like breast, prostate, and lung. As preclinical trials and case series mount (over 380 self-reported remissions by mid-2025) , this trio emerges as a low-cost, accessible booster for those navigating advanced disease.  But evidence varies—strong for curcumin's synergies, emerging for the others—and always pair with professional oversight. At OneDayMD, we sift the science to empower you: let's explore the mechanisms, data, and real-world application. Fenbendazole's Core Action: A Primer for Synergy Fenbendazole (FBZ), the benzi...